Welcome to our dedicated page for Pulmatrix SEC filings (Ticker: PULM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pulmatrix, Inc. (PULM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer listed on Nasdaq. These filings document material events, financial performance and key developments affecting Pulmatrix’s inhaled therapeutic pipeline and strategic transactions.
Investors can review Pulmatrix’s Current Reports on Form 8-K, which the company uses to report significant events such as quarterly financial results, corporate updates and merger-related developments. For example, Pulmatrix has filed 8-Ks furnishing press releases on its first, second and third quarter 2025 financial results and corporate updates, as well as an 8-K describing a mutual waiver agreement related to its merger agreement with Cullgen Inc. These filings incorporate press releases that discuss Pulmatrix’s iSPERSE™-based programs, cost-saving measures and anticipated cash runway.
Filings associated with the proposed merger with Cullgen are particularly relevant. Pulmatrix references a registration statement on Form S-4, which was declared effective by the SEC, and stockholder approval of the merger and related proposals. While the Form S-4 itself is filed separately, related 8-Ks and other Exchange Act reports provide context on the transaction structure, closing conditions and subsequent waiver arrangements between Pulmatrix and Cullgen.
Through this page, users can also monitor Pulmatrix’s periodic reports, such as Forms 10-K and 10-Q (when available in the feed), which typically contain detailed discussions of its clinical programs, iSPERSE™ patent portfolio, collaborations with partners like Cipla and MannKind Corporation, and risk factors. Form 4 and other insider transaction filings, when present, can help readers understand equity activity by directors and officers.
Stock Titan enhances these SEC documents with AI-powered summaries that explain the key points of lengthy filings in plain language. Real-time updates from EDGAR ensure that new Pulmatrix filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports and Form 4 insider trading disclosures, are quickly reflected. This allows investors and researchers to navigate Pulmatrix’s regulatory history and understand how clinical, financial and strategic developments are formally reported to the SEC.
Pulmatrix has signed a definitive agreement to merge with privately held Eos SENOLYTIX, a gerotherapeutics company targeting aging-related mitochondrial dysfunction. Pulmatrix will acquire Eos via a stock-for-stock merger, with Eos becoming a wholly owned subsidiary.
Based on the expected exchange ratio, pre‑Merger Eos stakeholders, including new financing investors and fee shares, are expected to own about 94% of the combined company on a fully diluted basis, while existing Pulmatrix stockholders will own about 6%. The combined entity will be renamed Eos SENOLYTIX, Inc. and is expected to trade on Nasdaq under the ticker "EOSX" if the transaction closes.
Alongside the Merger, Pulmatrix agreed to a $1 million private placement of Series B Convertible Preferred Stock at a stated value of $1,000 per share, convertible at $2.20 per share and carrying an 8% cumulative dividend payable in stock. These preferred shares vote with common stock and are subject to a 180‑day lock‑up and strong transfer restrictions.
Eos separately arranged an up to $18 million financing through convertible notes and equity, plus an additional planned Series A preferred round, to fund its MitoXcel™ platform and lead candidate PTC‑2105. The Merger and financings remain subject to stockholder approvals, Nasdaq listing approval, Form S‑4 effectiveness and other customary closing conditions.
Pulmatrix, Inc. and Eos SENOLYTIX, Inc. entered a definitive merger agreement under which Pulmatrix will acquire Eos and the combined company will operate as Eos SENOLYTIX, Inc. and is expected to trade on Nasdaq as EOSX. The transaction includes concurrent private financings totaling $19 million to support advancement of Eos’s MitoXcel™ platform and lead clinical candidate PTC-2105 for sarcopenia and sarcopenic obesity. The boards of both companies unanimously approved the Merger, which is expected to close in mid-2026, subject to customary closing conditions including stockholder approvals and effectiveness of a Form S-4 registration statement. Following closing and payment of placement and advisory fees, pre-Merger Pulmatrix stockholders are expected to own approximately 6% of the combined company and pre-Merger Eos stockholders are expected to own approximately 94%.
Pulmatrix, Inc. announced that Cullgen Inc. has terminated their previously agreed merger and all related transactions under the Merger Agreement. No termination fee will be paid by either party, and each will cover its own costs and expenses associated with the deal.
The merger, originally signed in November 2024 and approved by Pulmatrix stockholders in June 2025, had been awaiting approval from the China Securities Regulatory Commission, which was not obtained before Cullgen’s termination on February 28, 2026. Pulmatrix states that it continues to pursue alternative merger opportunities while highlighting its proprietary iSPERSE™ inhaled drug-delivery technology and clinical assets.
Pulmatrix, Inc. describes a company in transition that now depends heavily on a proposed merger with Cullgen to define its future. The Merger has been approved by Pulmatrix stockholders but still requires several closing conditions, including approval from China’s securities regulator, and may be delayed or terminated.
While awaiting completion, Pulmatrix has paused development of its iSPERSE™-based drug candidates PUR3100 for acute migraine, PUR1800 for COPD exacerbations, and PUR1900 for fungal lung disease, and is instead seeking ways to monetize these assets. Cipla has taken over most development and commercialization costs for PUR1900 outside the United States, where Pulmatrix would receive a 2% royalty on any potential future net sales.
The company emphasizes the strength of its inhaled dry powder iSPERSE™ platform and a large patent estate but reports only two full-time employees and minimal recent research spending. Management warns that if the Cullgen merger or other strategic transactions do not succeed, the board may consider dissolving and liquidating the company.
Pulmatrix, Inc. reported 2025 results showing a sharp shift to a leaner, pre‑revenue profile while pursuing a planned merger with Cullgen. Revenues fell to $0 for the year ended December 31, 2025, compared to $7.8 million in 2024, reflecting the wind down of the PUR1900 program and related Cipla agreement.
Research and development expenses dropped to about $0.1 million from $7.2 million, and general and administrative expenses declined to $5.1 million from $7.8 million, helping narrow the net loss to $5.2 million from $9.6 million. Cash and cash equivalents were $4.1 million at year-end 2025, down from $9.5 million, and the company anticipates this will fund operations into the first quarter of 2027.
The update highlights progress toward the proposed merger with Cullgen, which has been approved by Pulmatrix stockholders but remains subject to additional conditions, including Nasdaq listing approval and clearance from the China Securities Regulatory Commission. Pulmatrix and Cullgen have waived the merger’s “No Solicitation” clause, allowing both to explore alternative transactions. Pulmatrix is also actively seeking to license or monetize its iSPERSE™ technology and three associated clinical programs, including a Phase 2‑ready acute migraine candidate.
Pulmatrix, Inc. reported that on December 17, 2025 it entered into a mutual waiver agreement with Cullgen Inc. and PLC Merger Sub, Inc. related to their existing Merger Agreement. The waiver allows all parties to forego compliance with Section 5.4 of the Merger Agreement, which had imposed certain restrictions on each party during the pre-closing period. The company stated that, aside from this specific waiver, the Merger Agreement remains in full force and effect and no other terms have been amended, waived, or modified. Pulmatrix also issued a press release on December 18, 2025 describing the waiver, which is furnished as an exhibit.
Pulmatrix, Inc. furnished an 8-K announcing it issued a press release with financial results for the third fiscal quarter ended September 30, 2025, along with a corporate update. The press release is provided as Exhibit 99.1 and incorporated by reference.
Consistent with General Instruction B.2 to Item 2.02, the information in this report, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act.
Pulmatrix (PULM) filed its Q3 2025 10‑Q, reporting a narrower net loss as operating costs fell sharply while it advances a pending merger with Cullgen. For the quarter ended September 30, 2025, revenue was $0 versus $366,000 a year ago; net loss was $877,000 (vs. $2.6M). Research and development expense was $8,000 and general and administrative was $858,000. Cash and cash equivalents were $4.794M and stockholders’ equity was $4.733M.
Year‑to‑date, net loss was $4.234M (vs. $7.573M), with operating cash use of $4.727M. The company says existing cash will fund corporate operating expenses for at least the next 12 months from issuance. The Cullgen merger remains subject to Nasdaq listing and CSRC approval; under the Merger Agreement, Pulmatrix expects to declare a cash dividend to pre‑merger stockholders equal to net cash above $2.5M, subject to adjustments. On closing, pre‑Merger Cullgen holders are expected to own about 96.4% of the combined company on a fully‑diluted basis. As of October 13, 2025, shares outstanding were 3,652,285.
Pulmatrix (PULM) Q2-25 10-Q highlights: revenue fell to $0 from $1.6 m YoY as development work on PUR1900 wound down. Operating expenses dropped sharply to $1.5 m (-79%), driven by a 98% reduction in R&D to $14 k after the MannKind facility divestiture and staff cuts. Net loss narrowed to $1.5 m (-73%), or -$0.42/sh versus -$1.59/sh last year. Six-month net loss improved to $3.4 m from $5.0 m.
Cash & equivalents declined to $5.8 m (Dec-24: $9.5 m) after $3.7 m operating cash burn; management believes liquidity covers ≥12 months if the Cullgen merger is not completed. Stockholders’ equity fell to $5.6 m.
Cullgen merger: approved by Pulmatrix holders on 16-Jun-25; closing now targeted by 12-Oct-25 pending CSRC and Nasdaq approvals. Pre-merger Pulmatrix investors will receive a cash dividend for net cash above $2.5 m and retain only ~3.6% pro-forma ownership. Termination fees range from $0.42 m to $8.4 m. Failure to close could push Pulmatrix toward liquidation or require new funding.
Warrant liability was re-measured to $0, creating a $67 k gain; 918 k warrants remain outstanding, many expiring July-25. No ATM sales occurred in H1-25; share count steady at 3.65 m.